Johnson & Johnson

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

131,900

Employees131,900

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

131,900

Employees131,900

JNJ Key Statistics

Market cap

385.83B

Market cap385.83B

Price-Earnings ratio

23.17

Price-Earnings ratio23.17

Dividend yield

3.03%

Dividend yield3.03%

Average volume

5.50M

Average volume5.50M

High today

$160.71

High today$160.71

Low today

$158.78

Low today$158.78

Open price

$159.50

Open price$159.50

Volume

5.33M

Volume5.33M

52 Week high

$168.85

52 Week high$168.85

52 Week low

$143.13

52 Week low$143.13

JNJ News

Benzinga 2d

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization

On Friday, Johnson & Johnson JNJ announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to p...

Reuters 2d

J&J discontinues dengue drug study

(Reuters) -Johnson & Johnson said on Friday it will discontinue a mid-stage field study evaluating the efficacy of its antiviral drug candidate for the preventi...

Benzinga 4d

Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug

Wednesday, Johnson & Johnson JNJ revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s PFE Xtandi (enzalutamide). The da...

Analyst ratings

61%

of 23 ratings

Buy

39.1%

Hold

60.9%

Sell

More JNJ News

Reuters 5d

J&J to invest more than $2 billion in new manufacturing facility

(Reuters) -Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina, aiding product...

TipRanks 5d

J&J to invest more than $2B in manufacturing facility in North Carolina

Johnson & Johnson announced an investment of more than $2B to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. “The new faci...

Simply Wall St 5d

Johnson & Johnson is a favorite amongst institutional investors who own 73%

Key Insights Institutions' substantial holdings in Johnson & Johnson implies that they have significant influence over the company's share price The top 25 sh...

Seeking Alpha 6d

J&J submits supplemental BLA for Darzalex Faspro to FDA

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application for its drug Darzalex Faspro in combination with three other medications...

The Wall Street Journal 6d

J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program

Johnson & Johnson has dropped plans to change the way it offers drug discounts to certain hospitals, citing opposition by a federal agency that warned of penalt...

TipRanks 6d

Johnson & Johnson files for FDA approval of Darzalex Faspro-based regimen

Johnson & Johnson announced the submission of a supplemental Biologics License Application, or sBLA, to the FDA for approval of a new indication for Darzalex Fa...

Investor's Business Daily 6d

Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%

In this article: Legend Biotech reversed early gains Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death....